Associated Papers
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.
Chen Y et al.
Molecular Cancer Therapeutics, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_3.xlsx › KRAS_G12D_LOF_DMS_Screens
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA et al.
Cancer Research, 2023
KRAS inhibition in metastatic colorectal cancer: An update.
Nusrat M et al.
Current Opinion in Pharmacology, 2023
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H et al.
Cancer Communications (london, England), 2023
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A et al.
Cancer Discovery, 2022
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Reita D et al.
Cancers, 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T et al.
Scientific Reports, 2022
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D et al.
Molecular Cancer, 2021
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacological Research, 2021
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.
Haza KZ et al.
Nature Communications, 2021
Acquired Resistance to KRASG12C Inhibition in Cancer.
Awad MM et al.
The New England Journal of Medicine, 2021
Select a paper to view details